Device Trial Radar · NCT06994546
ArtiBest for Knee Osteoarthritis
Last checked: Nov 20, 2026Latest source record: May 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Mar 11, 2025
Primary completion
Nov 30, 2025
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- Maxigen Biotech Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 29, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 35 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the real-world effectiveness and safety of ArtiBest in the treatment of knee osteoarthritis. The main questions it aims to answer are: 1. The change from baseline The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at 26 weeks post injection. 2. The change from baseline VAS resting pain score at 12 and 26 weeks post injection. 3. The change from baseline The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain score at 12 weeks post injection. 4. The change from baseline Patient's Global Assessment PGA) using VAS scoring at 12 and 26 weeks post injection. 5. The OMERACT OARSI responder rate at 12 and 26 weeks post injection. 6. The VAS satisfaction score at 12 and 26 weeks post injection 7. The incidence of Adverse events reported during the study period. Participants will undergo a single injection of ArtiBest at treatment visit, and three follow up visits at week 4 , 12 , and 26.
Conditions
- Knee Osteoarthristis
Interventions
ArtiBest ® Intra articular InjectionDevice
single intra articular injection of 3 ml (one syringe) per knee joint. Each syringe contains 20 mg/mL sodium hyaluronate.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change of The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scoreTime frame: Week 0 and 26 weeks post injection
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.